PAYS

Paysign is a genuinely high-quality business hiding behind a scary-looking balance sheet. FY2025 revenue grew 40.5% to $82.0M, the fifth straight year of gains (up from $29.5M in 2021), while operating income exploded 620.8% to $7.36M and net income rose 97.9% to $7.55M — clear evidence that operating leverage is finally kicking in on a 59.4% gross-margin, vertically integrated platform. The balance sheet is pristine on a real-leverage basis: $165M cash against only ~$8M of total debt ($6.14M long-term + $1.86M current). The 4.70x liabilities/equity ratio is not financial gearing but customer card float — the $216M of current liabilities is largely prepaid-card balances Paysign holds and processes, the natural mechanics of a program manager. ROE is a healthy 15.6%. This is a profitable, self-funding compounder anchored in patient-affordability, plasma/donor-compensation and prepaid programs.

Two things keep me at hold rather than buy. First, valuation: at $8.26 the stock trades at 63.5x FY diluted EPS of $0.13 and 5.6x sales, a full price that requires the current 40%+ growth to persist for years. Second, management's own MD&A explicitly anticipates 'an inevitable decline in growth rates as our operating revenues increase' and warns it 'may also experience a decline in margins' — with net margin already thin at 9.2%, there is little cushion. Note too that the $52.5M operating cash flow flatters the picture: much of it reflects growth in customer card liabilities (float), not economic earnings attributable to shareholders, so the P/E is a fairer gauge of profitability than OCF.